Terms: = Breast cancer AND IRF4, LSIRF, 3662, ENSG00000137265, Q15306 AND Treatment
11 results:
1. Clinical efficacy and biomarker analysis of neoadjuvant camrelizumab plus chemotherapy for early-stage triple-negative breast cancer: a experimental single-arm phase II clinical trial pilot study.
Zheng C; Liu Y; Wang X; Bi Z; Qiu P; Qiao G; Bi X; Shi Z; Zhang Z; Chen P; Sun X; Wang C; Zhu S; Meng X; Song Y; Qi Y; Li L; Luo N; Wang Y
Int J Surg; 2024 Mar; 110(3):1527-1536. PubMed ID: 38116673
[TBL] [Abstract] [Full Text] [Related]
2. Effects of nonparticipation at previous screening rounds on the characteristics of screen-detected breast cancers.
Duijm LEM; Broeders MJM; Setz-Pels W; van Breest Smallenburg V; van Beek HC; Donkers-van Rossum AB; Slob MJ; Kuipers TP; Mann RM; Voogd AC
Eur J Radiol; 2022 Sep; 154():110391. PubMed ID: 35679699
[TBL] [Abstract] [Full Text] [Related]
3. A Machine Learning Model to Predict the Triple Negative breast cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract] [Full Text] [Related]
4. Detection significance of miR-3662, miR-146a, and miR-1290 in serum exosomes of breast cancer patients.
Li S; Zhang M; Xu F; Wang Y; Leng D
J Cancer Res Ther; 2021 Jul; 17(3):749-755. PubMed ID: 34269309
[TBL] [Abstract] [Full Text] [Related]
5. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
Choi JH; Jeon CW; Kim YO; Jung S
Medicine (Baltimore); 2020 Nov; 99(46):e23053. PubMed ID: 33181670
[TBL] [Abstract] [Full Text] [Related]
6. A parallel and cascade control system: magnetofection of miR125b for synergistic tumor-association macrophage polarization regulation and tumor cell suppression in breast cancer treatment.
Hu A; Chen X; Bi Q; Xiang Y; Jin R; Ai H; Nie Y
Nanoscale; 2020 Nov; 12(44):22615-22627. PubMed ID: 33150908
[TBL] [Abstract] [Full Text] [Related]
7. Inhibition of DNMT1 and ERRα crosstalk suppresses breast cancer via derepression of irf4.
Vernier M; McGuirk S; Dufour CR; Wan L; Audet-Walsh E; St-Pierre J; Giguère V
Oncogene; 2020 Oct; 39(41):6406-6420. PubMed ID: 32855526
[TBL] [Abstract] [Full Text] [Related]
8. DNA methylation markers panel can improve prediction of response to neoadjuvant chemotherapy in luminal B breast cancer.
Sigin VO; Kalinkin AI; Kuznetsova EB; Simonova OA; Chesnokova GG; Litviakov NV; Slonimskaya EM; Tsyganov MM; Ibragimova MK; Volodin IV; Vinogradov II; Vinogradov MI; Vinogradov IY; Kutsev SI; Strelnikov VV; Zaletaev DV; Tanas AS
Sci Rep; 2020 Jun; 10(1):9239. PubMed ID: 32514046
[TBL] [Abstract] [Full Text] [Related]
9. The Gut Microbiome: A New Player in breast cancer Metastasis.
Ingman WV
Cancer Res; 2019 Jul; 79(14):3539-3541. PubMed ID: 31308136
[TBL] [Abstract] [Full Text] [Related]
10. Role of STAT3 as a negative regulator in Mac2- binding protein expression.
Park YP; Kim JT; Yang Y; Lim JS; Yoon DY; Kim JW; Lee HG
Korean J Lab Med; 2008 Jun; 28(3):230-8. PubMed ID: 18594176
[TBL] [Abstract] [Full Text] [Related]
11. Incidence of breast carcinoma in women with thyroid carcinoma.
Vassilopoulou-Sellin R; Palmer L; Taylor S; Cooksley CS
Cancer; 1999 Feb; 85(3):696-705. PubMed ID: 10091743
[TBL] [Abstract] [Full Text] [Related]
